1. Home
  2. GOVX vs XAIR Comparison

GOVX vs XAIR Comparison

Compare GOVX & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

N/A

Current Price

$0.17

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

N/A

Current Price

$2.27

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GOVX
XAIR
Founded
2001
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
3.0M
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
GOVX
XAIR
Price
$0.17
$2.27
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$10.00
★ $20.00
AVG Volume (30 Days)
★ 111.0K
26.3K
Earning Date
11-12-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
$2,489,145.00
★ $7,679,000.00
Revenue This Year
N/A
$4.23
Revenue Next Year
N/A
$108.84
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 107.26
52 Week Low
$0.17
$0.33
52 Week High
$1,425.00
$8.19

Technical Indicators

Market Signals
Indicator
GOVX
XAIR
Relative Strength Index (RSI) 8.96 40.08
Support Level N/A $2.05
Resistance Level $8.64 $3.30
Average True Range (ATR) 0.16 0.16
MACD -0.15 0.06
Stochastic Oscillator 0.00 34.48

Price Performance

Historical Comparison
GOVX
XAIR

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.

About XAIR Beyond Air Inc.

Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.

Share on Social Networks: